drugset / Trial / NCT07493447
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Non-randomizedSingle-groupOpen-labelSupportive care
Summary
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
Timeline
- Start
- 2026-07
- Primary completion
- 2030-05
- Completion
- 2031-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 50 mg | Intravenous |
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 100 mg | Intravenous |